5
Clinical Trials associated with Somatropin biosimilar(Sedico BV)A Randomized Clinical Trial of Two Different Initial Growth Hormone Doses in Children With Growth Hormone Deficiency in the First Year of Treatment
A prospective, randomized, open-label single-blinded study of 50 subjects with growth hormone deficiency, ages 5 to 15 years in which 25 subjects will initiate rhGH therapy at 0.3mg/kg/week and the remaining 25 subjects will initiate their rhGH treatment at 0.2 mg/kg/week for the first 12 months of treatment. Safety parameters, height velocity, and adult height prediction by bone age determination will be assessed at 4-month intervals for 1 year following the initiation of rhGH therapy.
The Effect of Myo-inositol, Somatropin, and DHEA on Poor Ovarian Responders Undergoing ICSI : an Open Label Randomized Clinical Trial.
To evaulate the role of Myo-inositol, somatropin, DHEA on ICSI outcome in poor ovarian responder
Growth Hormone During Fasting. Signaltransduktion in Muscle and Adipose Tissue, Consequence of Growth Hormone Receptor Antagonist, Quantification of Intrahepatic Lipid Content Based on MR Scanning
The purpose of this study is to examine the effects of growth hormone during fasting in healthy lean men.
100 Clinical Results associated with Somatropin biosimilar(Sedico BV)
100 Translational Medicine associated with Somatropin biosimilar(Sedico BV)
100 Patents (Medical) associated with Somatropin biosimilar(Sedico BV)
100 Deals associated with Somatropin biosimilar(Sedico BV)